KRAS and colorectal carcinoma: Moreover, Lal et al. reported that the reduced infiltration of cytotoxic T cells and downregulation of the interferon gamma (IFN-γ) pathway was seen in KRAS-mutant CRC [26], and Liao et al. found that KRAS mutations induced an immune-suppressive profile by inhibiting interferon regulatory factor 2 (IRF2) expression and promoting the migration of MDSCs [27].